Krystal Biotech, Inc. (KRYS) Tops Q3 EPS by 404c

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $2.79, $4.04 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $6.29 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c